Published in Cancer on August 01, 2001
Combination Treatment of S-1 With Paclitaxel in Advanced Esophageal Cancer | NCT01704690
Barrett's oesophagus and oesophageal adenocarcinoma: time for a new synthesis. Nat Rev Cancer (2010) 3.27
Esophageal adenocarcinoma incidence in individuals with gastroesophageal reflux: synthesis and estimates from population studies. Am J Gastroenterol (2010) 2.37
NSAIDs modulate CDKN2A, TP53, and DNA content risk for progression to esophageal adenocarcinoma. PLoS Med (2007) 2.23
Trends in esophageal adenocarcinoma incidence and mortality. Cancer (2012) 2.03
Effect of a prior endoscopy on outcomes of esophageal adenocarcinoma among United States veterans. Gastrointest Endosc (2008) 1.96
Adenocarcinoma of oesophagus: what exactly is the size of the problem and who is at risk? Gut (2005) 1.74
Gastric acid suppression and risk of oesophageal and gastric adenocarcinoma: a nested case control study in the UK. Gut (2006) 1.67
Helicobacter pylori infection and the risk of Barrett's oesophagus: a community-based study. Gut (2007) 1.57
Staging accuracy of esophageal cancer by endoscopic ultrasound: a meta-analysis and systematic review. World J Gastroenterol (2008) 1.52
Reproducible two-dimensional capillary electrophoresis analysis of Barrett's esophagus tissues. Anal Chem (2006) 1.49
Waist-to-hip ratio, but not body mass index, is associated with an increased risk of Barrett's esophagus in white men. Clin Gastroenterol Hepatol (2012) 1.41
A prospective study of BMI and risk of oesophageal and gastric adenocarcinoma. Eur J Cancer (2008) 1.41
Prognostic biomarkers for esophageal adenocarcinoma identified by analysis of tumor transcriptome. PLoS One (2010) 1.33
Disparities in the classification of esophageal and cardia adenocarcinomas and their influence on reported incidence rates. Ann Surg (2006) 1.24
Incidence and survival of oesophageal and gastric cancer in England between 1998 and 2007, a population-based study. BMC Cancer (2012) 1.19
Psychosocial working conditions and the risk of esophageal and gastric cardia cancers. Eur J Epidemiol (2004) 1.18
Neoadjuvant treatment of esophageal cancer. World J Gastroenterol (2010) 1.17
Food group intake and risk of subtypes of esophageal and gastric cancer. Int J Cancer (2008) 1.17
Meta-analysis: the association of oesophageal adenocarcinoma with symptoms of gastro-oesophageal reflux. Aliment Pharmacol Ther (2010) 1.16
A Large-scale genetic association study of esophageal adenocarcinoma risk. Carcinogenesis (2010) 1.12
Barrett's esophagus and the increasing role of endoluminal therapy. Therap Adv Gastroenterol (2008) 1.11
Endoscopic mucosal resection for high-grade dysplasia and intramucosal carcinoma in Barrett's esophagus: an Italian experience. World J Gastroenterol (2005) 1.10
Cisplatin pharmacogenetics, DNA repair polymorphisms, and esophageal cancer outcomes. Pharmacogenet Genomics (2009) 1.09
The role of tobacco, alcohol, and obesity in neoplastic progression to esophageal adenocarcinoma: a prospective study of Barrett's esophagus. PLoS One (2013) 1.08
Principal component analysis of dietary and lifestyle patterns in relation to risk of subtypes of esophageal and gastric cancer. Ann Epidemiol (2011) 1.06
Matrix metalloproteinase 1, 3 and 12 polymorphisms and esophageal adenocarcinoma risk and prognosis. Carcinogenesis (2009) 1.06
Influence of surgery-related factors on quality of life after esophageal or cardia cancer resection. World J Surg (2005) 1.05
Epidemiology and biology of esophageal cancer. Gastrointest Cancer Res (2009) 1.04
Biodegradable esophageal stent placement does not prevent high-grade stricture formation after circumferential mucosal resection in a porcine model. Surg Endosc (2012) 1.04
Safety and efficacy of esophageal stents preceding or during neoadjuvant chemotherapy for esophageal cancer: a systematic review and meta-analysis. J Gastrointest Oncol (2014) 1.03
Helicobacter pylori and esophageal disease: wake-up call? Gastroenterology (2010) 1.03
Survival from cancer of the oesophagus in England and Wales up to 2001. Br J Cancer (2008) 1.01
Neoadjuvant versus adjuvant treatment: which one is better for resectable esophageal squamous cell carcinoma? World J Surg Oncol (2012) 0.99
Vascular endothelial growth factor polymorphisms and esophageal cancer prognosis. Clin Cancer Res (2009) 0.97
Current status of Barrett's esophagus research in Asia. J Gastroenterol Hepatol (2011) 0.96
Incidence and survival for gastric and esophageal cancer diagnosed in British Columbia, 1990 to 1999. Can J Gastroenterol (2008) 0.95
Metabolic risk factors for esophageal squamous cell carcinoma and adenocarcinoma: a prospective study of 580,000 subjects within the Me-Can project. BMC Cancer (2014) 0.95
Visceral obesity and the risk of Barrett's esophagus in Japanese patients with non-alcoholic fatty liver disease. BMC Gastroenterol (2009) 0.94
Natural history of Barrett's esophagus. World J Gastroenterol (2012) 0.93
Methylated DAPK and APC promoter DNA detection in peripheral blood is significantly associated with apparent residual tumor and outcome. J Cancer Res Clin Oncol (2009) 0.93
Cyclooxygenase inhibitors use is associated with reduced risk of esophageal adenocarcinoma in patients with Barrett's esophagus: a meta-analysis. Br J Cancer (2014) 0.92
The impact of obesity on the rise in esophageal adenocarcinoma incidence: estimates from a disease simulation model. Cancer Epidemiol Biomarkers Prev (2011) 0.91
Oesophageal adenocarcinoma is associated with a deregulation in the MYC/MAX/MAD network. Br J Cancer (2008) 0.91
The association between obesity factor and esophageal caner. J Gastrointest Oncol (2012) 0.90
Trends in the incidence of adenocarcinoma of the oesophagus and cardia in the Netherlands 1989-2003. Br J Cancer (2007) 0.90
Randomized controlled trial of laparoscopic gastric ischemic conditioning prior to minimally invasive esophagectomy, the LOGIC trial. Surg Endosc (2012) 0.90
Does the Incidence of Adenocarcinoma of the Esophagus and Gastric Cardia Continue to Rise in the Twenty-First Century?-a SEER Database Analysis. J Gastrointest Surg (2013) 0.88
Risk of esophagus cancer in diabetes mellitus: a population-based case-control study in Taiwan. BMC Gastroenterol (2012) 0.88
Esophageal cancer in Germany is associated with Epstein-Barr-virus but not with papillomaviruses. Med Microbiol Immunol (2002) 0.87
Diet and lifestyle factors and risk of subtypes of esophageal and gastric cancers: classification tree analysis. Ann Epidemiol (2013) 0.87
Impact of histone deacetylase 1 and metastasis-associated gene 1 expression in esophageal carcinogenesis. Oncol Lett (2014) 0.85
Helicobacter pylori: friend or foe? World J Gastroenterol (2014) 0.85
Epidermal growth factor receptor expression in esophageal adenocarcinoma: relationship with tumor stage and survival after esophagectomy. Gastroenterol Res Pract (2012) 0.84
Probing the link between oestrogen receptors and oesophageal cancer. World J Surg Oncol (2010) 0.84
Advances in Endoscopic Visualization of Barrett's Esophagus: The Role of Confocal Laser Endomicroscopy. Gastroenterol Res Pract (2012) 0.84
Reduced esophageal cancer incidence in statin users, particularly with cyclo-oxygenase inhibition. World J Gastrointest Pharmacol Ther (2013) 0.84
Accuracy of endoscopic ultrasound in the diagnosis of distal and celiac axis lymph node metastasis in esophageal cancer: a meta-analysis and systematic review. Dig Dis Sci (2007) 0.83
Long noncoding RNA PEG10 regulates proliferation and invasion of esophageal cancer cells. Cancer Gene Ther (2015) 0.83
Differential SPARC mRNA expression in Barrett's oesophagus. Br J Cancer (2003) 0.83
Iron intake and body iron stores as risk factors for Barrett's esophagus: a community-based study. Am J Gastroenterol (2008) 0.83
Reflux esophagitis, high-grade neoplasia, and early Barrett's carcinoma-what is the place of the Merendino procedure? Langenbecks Arch Surg (2008) 0.83
Regional variations in esophageal cancer rates by census region in the United States, 1999-2008. PLoS One (2013) 0.83
Clinical puzzle: Barrett's oesophagus. Dis Model Mech (2008) 0.82
None-endoscopic Screening for Esophageal Squamous Cell Carcinoma- A Review. Middle East J Dig Dis (2012) 0.82
Trends in esophageal cancer and body mass index by race and gender in the state of Michigan. BMC Gastroenterol (2009) 0.82
The use of LigaSure Vessel Sealing System in Ivor Lewis esophagectomy. J Cardiothorac Surg (2012) 0.81
Single nucleotide polymorphisms in the matrix metalloproteinase gene family and the frequency and duration of gastroesophageal reflux disease influence the risk of esophageal adenocarcinoma. Int J Cancer (2012) 0.81
Forthcoming prognostic markers for esophageal cancer: a systematic review and meta-analysis. J Gastrointest Oncol (2014) 0.81
Prevalence of Barrett's Esophagus in Asian Countries: A Systematic Review and Meta-analysis. Clin Gastroenterol Hepatol (2015) 0.81
Current treatment options for the management of esophageal cancer. Cancer Manag Res (2012) 0.81
Long-term management of gastroesophageal reflux disease with pantoprazole. Ther Clin Risk Manag (2007) 0.81
Trends in esophageal cancer survival in United States adults from 1973 to 2009: A SEER database analysis. J Gastroenterol Hepatol (2016) 0.80
Oesophageal cancer mortality in Spain: a spatial analysis. BMC Cancer (2007) 0.80
Sentinel lymph node in oesophageal cancer-a systematic review and meta-analysis. J Gastrointest Oncol (2014) 0.80
Prevalence of dysphagia in patients with gastroesophageal reflux in Germany. Dysphagia (2008) 0.80
Cytochrome P450 levels are altered in patients with esophageal squamous-cell carcinoma. World J Gastroenterol (2007) 0.80
Preliminary results of antiscarring therapy in the prevention of postendoscopic esophageal mucosectomy strictures. Surg Endosc (2013) 0.79
Nurse-led follow-up of patients after oesophageal or gastric cardia cancer surgery: a randomised trial. Br J Cancer (2008) 0.79
Video. Surgical optimisation of the gastric conduit for minimally invasive oesophagectomy. Surg Endosc (2011) 0.79
MicroRNA signature characterizes primary tumors that metastasize in an esophageal adenocarcinoma rat model. PLoS One (2015) 0.79
Presence of Epstein-Barr virus in esophageal cancer is restricted to tumor infiltrating lymphocytes. Med Microbiol Immunol (2005) 0.78
Sentinel lymph node biopsy in esophageal cancer: an essential step towards individualized care. Ann Surg Innov Res (2014) 0.78
Osteopontin (OPN/SPP1) isoforms collectively enhance tumor cell invasion and dissemination in esophageal adenocarcinoma. Oncotarget (2015) 0.78
Body measures in relation to gastro-oesophageal reflux. Gut (2007) 0.78
Targeted therapies for metastatic esophagogastric cancer. Curr Treat Options Oncol (2011) 0.78
Association of dietary fat intakes with risk of esophageal and gastric cancer in the NIH-AARP diet and health study. Int J Cancer (2012) 0.78
Treatment strategies for oesophageal cancer - time-trends and long term outcome data from a large tertiary referral centre. Radiat Oncol (2012) 0.77
Genome wide single cell analysis of chemotherapy resistant metastatic cells in a case of gastroesophageal adenocarcinoma. BMC Cancer (2011) 0.77
Statins and aspirin for chemoprevention in Barrett's esophagus: results of a cost-effectiveness analysis. Cancer Prev Res (Phila) (2013) 0.77
Esophageal cancer 2015, more questions than answers. J Gastrointest Oncol (2015) 0.77
Polymorphisms of MTHFR and susceptibility to oesophageal adenocarcinoma in a Caucasian United Kingdom population. World J Gastroenterol (2014) 0.76
An age-period-cohort analysis of obesity and incident esophageal adenocarcinoma among white males. Dis Esophagus (2016) 0.76
Duodeno-gastric-esophageal reflux--what is pathologic? Comparison of patients with Barrett's esophagus and age-matched volunteers. J Gastrointest Surg (2007) 0.76
Prognosis of surgery combined with different adjuvant therapies in esophageal cancer treatment: a network meta-analysis. Oncotarget (2017) 0.75
Familial Barrett's esophagus: clues to genetic risks for esophageal adenocarcinoma. Dig Dis Sci (2011) 0.75
Targeted therapy for esophagogastric cancers: a review. Onco Targets Ther (2012) 0.75
Pneumo-CT assessing response to neoadjuvant therapy in esophageal cancer: Imaging-pathological correlation. World J Gastrointest Oncol (2013) 0.75
Area-level attributes and esophageal adenocarcinoma in surveillance, epidemiology and end results registries. PLoS One (2013) 0.75
Epidermal growth factor receptor and HER2-neu mRNA expression in non-small cell lung cancer Is correlated with survival. Clin Cancer Res (2001) 2.28
Splenectomy in proximal gastric cancer: frequency of lymph node metastasis to the splenic hilus. J Surg Oncol (2001) 2.20
[German S3-guideline "Diagnosis and treatment of esophagogastric cancer"]. Z Gastroenterol (2011) 1.74
High rate of lymph-node metastasis in submucosal esophageal squamous-cell carcinomas and adenocarcinomas. Endoscopy (2006) 1.66
Options in the management of esophageal perforation: analysis over a 12-year period. Dis Esophagus (2009) 1.63
Preoperative risk analysis in patients with adenocarcinoma or squamous cell carcinoma of the oesophagus. Br J Surg (2000) 1.61
[Regression of oesophageal carcinomas after neoadjuvant radiochemotherapy: criteria of the histopathological evaluation]. Pathologe (2004) 1.53
[18F]-fluorodeoxyglucose-positron emission tomography for the assessment of histopathologic response and prognosis after completion of neoadjuvant chemotherapy in gastric cancer. J Surg Oncol (2010) 1.49
p21/waf1/cip1 in gastric cancer: associations with histopathological subtypes, lymphonodal metastasis, prognosis and p53 status. Scand J Gastroenterol (2001) 1.42
The resection of the azygos vein--necessary or redundant extension of transthoracic esophagectomy? J Gastrointest Surg (2008) 1.41
[Cardia cancer: attempt at a therapeutically relevant classification]. Chirurg (1987) 1.35
High volume centers for esophagectomy: what is the number needed to achieve low postoperative mortality? Dis Esophagus (2004) 1.33
Molecular biology of esophageal cancer. Onkologie (2004) 1.28
[Does Charlson-comorbidity index correlate with short-term outcome in patients with gastric cancer?]. Zentralbl Chir (2003) 1.26
Staging of gastric cancer: correlation of lymph node size and metastatic infiltration. AJR Am J Roentgenol (1999) 1.23
Significance of lymph node involvement at the hepatic hilum in the resection of colorectal liver metastases. Br J Surg (1997) 1.23
Frequency of nodal metastases to the upper mediastinum in Barrett's cancer. Ann Surg Oncol (2002) 1.20
Adenomatous polyposis coli gene promoter hypermethylation in non-small cell lung cancer is associated with survival. Oncogene (2001) 1.17
Lymph node size and metastatic infiltration in colon cancer. Ann Surg Oncol (1999) 1.15
Expression of MMP-2 is associated with progression and lymph node metastasis of gastric carcinoma. Histopathology (2001) 1.14
Management of upper intestinal leaks using an endoscopic vacuum-assisted closure system (E-VAC). Surg Endosc (2013) 1.14
Adipose tissue macrophages inhibit adipogenesis of mesenchymal precursor cells via wnt-5a in humans. Int J Obes (Lond) (2011) 1.13
Synthesis and configurational assay of asymmetric methyl groups. Eur J Biochem (1970) 1.11
Comparative evaluation of the prognostic value of MUC1, MUC2, sialyl-Lewis(a) and sialyl-Lewis(x) antigens in colorectal adenocarcinoma. Histopathology (2002) 1.08
Clinicopathological significance of MMP-2 and its specific inhibitor TIMP-2 in gastric cancer. Histol Histopathol (2008) 1.08
Histological type of esophageal cancer might affect response to neo-adjuvant radiochemotherapy and subsequent prognosis. Ann Oncol (2008) 1.01
Asymmetric methyl groups, and the mechanism of malate synthase. Nature (1969) 0.99
[Current S3 guidelines on surgical treatment of gastric carcinoma]. Chirurg (2012) 0.98
[Accidentally swallowed dentures--what is the correct diagnostic and therapeutic management?]. Zentralbl Chir (2008) 0.98
Function of the intrathoracic stomach as esophageal replacement. World J Surg (1988) 0.97
Endodissection of the thoracic esophagus. Technique and clinical results in transhiatal esophagectomy. Ann Surg (1993) 0.97
Immunoreactivity of Lewis blood group and mucin peptide core antigens: correlations with grade of dysplasia and malignant transformation in the colorectal adenoma-carcinoma sequence. Histol Histopathol (2002) 0.95
Comparative analysis of four histopathological classification systems to discriminate benign and malignant behaviour in gastrointestinal stromal tumors. Anticancer Res (2008) 0.94
Thomsen-Friedenreich antigen presents as a prognostic factor in colorectal carcinoma: A clinicopathologic study of 264 patients. Cancer (2000) 0.94
Return of interdigestive motor complex after abdominal surgery. End of postoperative ileus? Dig Dis Sci (1991) 0.94
Portal hyperperfusion causes disturbance of microcirculation and increased rate of hepatocellular apoptosis: investigations in heterotopic rat liver transplantation with portal vein arterialization. Transplant Proc (2006) 0.93
Prognostic impact of nodal micrometastasis in early esophageal cancer. Eur J Surg Oncol (2012) 0.91
Immunoreactivity of cytokeratins (CK7, CK20) and mucin peptide core antigens (MUC1, MUC2, MUC5AC) in adenocarcinomas, normal and metaplastic tissues of the distal oesophagus, oesophago-gastric junction and proximal stomach. Histopathology (2003) 0.90
Increased galectin-3 expression in gastric cancer: correlations with histopathological subtypes, galactosylated antigens and tumor cell proliferation. Tumour Biol (2000) 0.90
[En-bloc resection of the esophagus in esophageal cancer]. Langenbecks Arch Chir (1988) 0.89
Survivin expression in gastric cancer: Association with histomorphological response to neoadjuvant therapy and prognosis. J Surg Oncol (2009) 0.88
Alternative shift models and the quality of patient care. An empirical study in surgical intensive care units. Langenbecks Arch Surg (2001) 0.88
[Carcinoma of the esophagus--actual epidemiology in Germany]. Onkologie (2001) 0.88
[Diagnosis of and therapy for gastric cancer--work-flow]. Zentralbl Chir (2009) 0.87
Coincidence of nutritional habits and esophageal cancer in Germany. Onkologie (2001) 0.87
Esophageal cancer in Germany is associated with Epstein-Barr-virus but not with papillomaviruses. Med Microbiol Immunol (2002) 0.87
Preoperative lymph-node staging in gastrointestinal cancer--correlation between size and tumor stage. Onkologie (2002) 0.87
Barrett's esophagus: what is the poison - alkaline, biliary or acidic reflux? Dis Esophagus (2002) 0.87
Preoperative staging and risk analysis in esophageal carcinoma. Hepatogastroenterology (1990) 0.86
Increased c-myb mRNA expression in Barrett's esophagus and Barrett's-associated adenocarcinoma. J Surg Res (2001) 0.86
Microcirculatory changes associated with gastric tube formation in the pig. Eur Surg Res (2002) 0.86
MicroRNA profiling in locally advanced esophageal cancer indicates a high potential of miR-192 in prediction of multimodality therapy response. Int J Cancer (2013) 0.85
Liver transplantation for hilar cholangiocarcinoma: a German survey. Transplant Proc (2008) 0.85
Improved technique of heterotopic auxiliary rat liver transplantation with portal vein arterialization. Langenbecks Arch Surg (2006) 0.85
[Malignant tumors of the hepatic bifurcation--results of surgical therapy and prognostic factors]. Chirurg (1997) 0.85
Chronic esophagitis and subsequent morphological changes of the esophageal mucosa in Barrett's esophagus: a histological study of esophagectomy specimens. Surg Today (1994) 0.85
[Transmediastinal esophagectomy]. Langenbecks Arch Chir (1986) 0.85
Bile exposure of the denervated stomach as an esophageal substitute. Ann Thorac Surg (2001) 0.84
[Squamous cell cancer of the esophagus. Treatment concept at the surgical clinic of the Munich Technical University]. Chirurg (1992) 0.84
The "steakhouse syndrome". Primary and definitive diagnosis and therapy. Surg Endosc (1989) 0.84
Serosal penetration is an important prognostic factor for gastrointestinal stromal tumors. Oncol Rep (2008) 0.84
Competition between native liver and graft in auxiliary liver transplantation in a rat model. Transplant Proc (2008) 0.84
Thoracoscopic enucleation of esophageal leiomyomas: a feasible and safe procedure. Endoscopy (2007) 0.84
[Submucosal infiltration and local recurrence in pT1 low-risk rectal cancer treated by transanal endoscopic microsurgery]. Chirurg (2005) 0.84
Prognostic differences between early squamous-cell and adenocarcinoma of the esophagus. Dis Esophagus (1997) 0.84
Immunoreactivity of monoclonal antibody BW835 represents a marker of progression and prognosis in early gastric cancer. Oncology (2001) 0.83
Differential SPARC mRNA expression in Barrett's oesophagus. Br J Cancer (2003) 0.83
[Prevalence of reflux symptoms in the general population of Cologne]. Z Gastroenterol (2007) 0.83
[Anisoperistaltic Roux-en-Y reconstruction: rare cause for recurrent cholangitis after hepatic jejunostomy]. Chirurg (1999) 0.83
Lack of prognostic significance of serum DNA methylation of DAPK, MGMT, and GSTPI in patients with non-small cell lung cancer. J Surg Oncol (2009) 0.83
A double-blind study of pantoprazole and omeprazole in the treatment of reflux oesophagitis: a multicentre trial. Aliment Pharmacol Ther (1995) 0.83
Myotomy for esophageal achalasia - laparoscopic versus peroral endoscopic approach. Endoscopy (2010) 0.83
Reflux esophagitis, high-grade neoplasia, and early Barrett's carcinoma-what is the place of the Merendino procedure? Langenbecks Arch Surg (2008) 0.83
Evaluation of histological regression grading systems in the neoadjuvant therapy of rectal cancer: do they have prognostic impact? Int J Colorectal Dis (2012) 0.83
Multiple giant leiomyomas of the esophagus and stomach. Dis Esophagus (2006) 0.82
Expression of mucin-associated carbohydrate core antigens in esophageal squamous cell carcinomas. Anticancer Res (2001) 0.82
Upregulation of ornithine decarboxylase mRNA expression in Barrett's esophagus and Barrett's-associated adenocarcinoma. J Gastrointest Surg (2001) 0.82
Experimental bile duct protection by intraductal cooling during radiofrequency ablation. Br J Surg (2005) 0.82
Histopathologic characteristics of early adenocarcinoma in Barrett's esophagus. Cancer (1991) 0.82
Intraoperative changes of mucosal pCO2 during gastric tube formation. Langenbecks Arch Surg (2001) 0.82
GNAS1 T393C polymorphism is associated with histopathological response to neoadjuvant radiochemotherapy in esophageal cancer. Pharmacogenomics J (2009) 0.82
Classification, diagnosis and surgical treatment of carcinomas of the gastroesophageal junction. Hepatogastroenterology (2001) 0.81
[Preoperative colonoscopy before esophagectomy and reconstruction with gastric interposition]. Chirurg (2004) 0.81
Interaction of gastroesophageal reflux and esophageal motility. Evaluation by ambulatory 24-hour manometry and pH-metry. Dig Dis Sci (1992) 0.81
Perioperative treatment with filgrastim stimulates granulocyte function and reduces infectious complications after esophagectomy. Ann Hematol (2000) 0.81
Clinicopathologic and prognostic factors of young and elderly patients with esophageal adenocarcinoma: is there really a difference? Dis Esophagus (2008) 0.81
Prognostic factors in definitive radiochemotherapy of advanced inoperable esophageal cancer. Dis Esophagus (2011) 0.81
Supraventricular tachyarrhythmia as early indicator of a complicated course after esophagectomy. Dis Esophagus (2005) 0.81
Current strategy in surgery for esophageal cancer. Ann Ital Chir (1992) 0.81